VRCA Q2 2022 Earnings — Verrica Pharmaceuticals Inc. Revenue & Financial Results | Market Cap Arena

VRCAVerrica Pharmaceuticals Inc.

$57M

Q2 2022 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$214,000

Gross Profit

-$5,000-2.3% margin

Operating Income

-$9M-4262.1% margin

Net Income

-$10M-4751.4% margin

EPS (Diluted)

$-3.69

QoQ Revenue Growth

-50.3%

Cash Flow

Operating Cash Flow

-$7M

Free Cash Flow

-$7M

Stock-Based Comp.

$1M

Balance Sheet

Total Assets

$63M

Total Liabilities

$47M

Stockholders' Equity

$16M

Cash & Equivalents

$5M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$214,000	$0	—
Gross Profit	-$5,000	-$94,000	+94.7%
Operating Income	-$9M	-$11M	+15.0%
Net Income	-$10M	-$12M	+13.6%